lu 135252 has been researched along with Uremia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brochu, E; Grose, JH; Kingma, I; Lacasse, S; Larivière, R; Lebel, M; Moreau, C | 1 |
Amann, K; Balajew, V; Hergenröder, S; Mall, G; Münter, K; Ritz, E; Wagner, J; Wessels, S | 1 |
2 other study(ies) available for lu 135252 and Uremia
Article | Year |
---|---|
Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats.
Topics: Animals; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Kidney; Kidney Failure, Chronic; Male; Osmolar Concentration; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptors, Endothelin; Uremia | 1999 |
Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Capillaries; Coronary Circulation; Endothelin Receptor Antagonists; Endothelin-1; Immunohistochemistry; In Situ Hybridization; Indoles; Male; Molecular Biology; Myocardium; Nephrectomy; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger; Uremia | 2000 |